Company & Sponsor Intelligence
Sanofi
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting1
Completed1
Countries2
Therapeutic footprint
alzheimersepilepsyneuroimmunologyneuromuscular
Indexed studies
NCT02667496Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT05132569Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
neuromuscular · United StatesPHASE3
neuromuscular · United StatesPHASE3
NCT06714448A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
epilepsy · FranceCOMPLETED
epilepsy · FranceCOMPLETED
NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
neuroimmunology · United StatesPHASE3
neuroimmunology · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →